Anavex Life Sciences Corp.

NASDAQ:AVXL

12.56 (USD) • At close December 26, 2024
Bedrijfsnaam Anavex Life Sciences Corp.
Symbool AVXL
Munteenheid USD
Prijs 12.56
Beurswaarde 1,065,282,680
Dividendpercentage 0%
52-weken bereik 3.25 - 14.441
Industrie Biotechnology
Sector Healthcare
CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Website https://www.anavex.com

An error occurred while fetching data.

Over Anavex Life Sciences Corp.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to

Vergelijkbare Aandelen

Alector, Inc. logo

Alector, Inc.

ALEC

1.82 USD

DocGo Inc. logo

DocGo Inc.

DCGO

4.38 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

33.5 USD

Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc.

ORGO

3.28 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

6.65 USD

NanoString Technologies, Inc. logo

NanoString Technologies, Inc.

NSTG

0.105 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

21.91 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)